<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320597">
  <stage>Registered</stage>
  <submitdate>14/09/2009</submitdate>
  <approvaldate>13/10/2009</approvaldate>
  <actrnumber>ACTRN12609000893202</actrnumber>
  <trial_identification>
    <studytitle>Cognitive Changes With Adjuvant Therapy For Breast Cancer: A Longitudinal Study</studytitle>
    <scientifictitle>Longitudinal study assessing changes in cognitive function induced by adjuvant therapy in women with early stage breast cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>breast cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>No intervention related to the trial - only observation of changes in cognitive function induced by adjuvant therapy over the first two years from initiation of treatment (the choice of which is not influenced by participation in this study).</interventions>
    <comparator>Each patient is being assessed longitudinally and will serve as their own control.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The incidence of deficits in cognitive function associated with adjuvant therapies for breast cancer over a 2 year period using questionnaires and tests of memory, concentration, processing skills and task completion.</outcome>
      <timepoint>Assessed at 3 months, 6 months 12 months and 24 months from study entry (in comparison to baseline evaluation)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The time course of deficits in cognitive function associated with adjuvant therapies for breast cancer over a 2 year period.</outcome>
      <timepoint>Assessed at 3 months, 6 months 12 months and 24 months from study entry (in comparison to baseline evaluation)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in quality of life during adjuvant therapies for breast cancer using the European Organisation for Research and Treatment of Cancer (EORTC) QLQC30 quality of life questionnaire</outcome>
      <timepoint>Assessed at 3 months, 6 months 12 months and 24 months from study entry (in comparison to baseline evaluation)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in mood during adjuvant therapies for breast cancer assessed using questionnaires</outcome>
      <timepoint>Assessed at 3 months, 6 months 12 months and 24 months from study entry (in comparison to baseline evaluation)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The role played by menopausal status in cognitive functioning during adjuvant therapies for breast cancer (with menopausal status established by direct questioning of patients)</outcome>
      <timepoint>Assessed at 3 months, 6 months 12 months and 24 months from study entry (in comparison to baseline evaluation)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Women diagnosed with early breast cancer treated by surgery with curative intent
2. Adjuvant therapy is planned (chemotherapy, hormone therapy, radiotherapy, or any combination of the above)
3. Fluency in English</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Current use of hormone replacement therapy or hormonal contraception
2. Severe current mental illness
3. Not able to comply with the test requirements
4. Pre-existing significant neurological impairment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Psychosocial</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>20/11/2003</anticipatedstartdate>
    <actualstartdate>20/11/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate>23/09/2010</actualenddate>
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Michael Jameson</primarysponsorname>
    <primarysponsoraddress>Regional Cancer Centre
Waikato Hospital
Private Bag 3200
Hamilton 3240</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Waikato Medical Research Foundation</fundingname>
      <fundingaddress>Peter Rothwell Academic Centre
Private Bag 3200
Hamilton 3240</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Genesis Oncology Trust</fundingname>
      <fundingaddress>PO Box 17-188
Greenlane 1546
Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Bay Cancer Research &amp; Support Trust</fundingname>
      <fundingaddress>PO Box 2636
Tauranga 3110</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Waikato District Health Board</sponsorname>
      <sponsoraddress>Private Bag 3200
Hamilton 3240</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Barbara Hedge</othercollaboratorname>
      <othercollaboratoraddress>Dept of Psychology
University of Waikato 
Private Bag 3105
Hamilton 3240</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients receiving adjuvant treatment with chemotherapy commonly complain of impaired mental functioning during and after treatment. This study evaluates changes in various aspects of mental function starting before any adjuvant treatment and at various time points up to 2 years later.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Waikato Ethics Committee</ethicname>
      <ethicaddress>PO Box 1031
Hamilton 3240</ethicaddress>
      <ethicapprovaldate>29/07/2003</ethicapprovaldate>
      <hrec>WAI/03/05/033</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Michael Jameson</name>
      <address>Regional Cancer Centre
Waikato Hospital
Private Bag 3200
Hamilton 3240</address>
      <phone>+64 7 839 8604</phone>
      <fax>+64 7 839 8778</fax>
      <email>jameson@waikatodhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Michael Jameson</name>
      <address>Regional Cancer Centre
Waikato Hospital
Private Bag 3200
Hamilton 3240</address>
      <phone>+64 7 839 8604</phone>
      <fax>+64 7 839 8778</fax>
      <email>michael.jameson@waikatodhb.health.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Michael Jameson</name>
      <address>Regional Cancer Centre
Waikato Hospital
Private Bag 3200
Hamilton 3240</address>
      <phone>+64 7 839 8604</phone>
      <fax>+64 7 839 8778</fax>
      <email>michael.jameson@waikatodhb.health.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Jameson</name>
      <address>Regional Cancer Centre Waikato Hospital Private Bag 3200 Hamilton 3240</address>
      <phone>+64 7 839 8604</phone>
      <fax>+64 7 839 8778</fax>
      <email>michael.jameson@waikatodhb.health.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>